HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 33/4/852    most recent 09031936.00130507v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Xu, T. Articles by Wang, H. Search for Related Content PubMed PubMed Citation Articles by Xu, T. Articles by Wang, H.

Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice

¹ Dept of Pathophysiology, College of Veterinary Medicine, China Agricultural University, Beijing, China, and ² Dept of Veterinary Medicine, College of Animal Science, Hebei North University, Hebei Province, China.

CORRESPONDENCE: J. Qiao, Dept of Pathophysiology, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China. Fax: 86 1062733961. E-mail: qiaojian{at}cau.edu.cn

Keywords: Acute respiratory distress syndrome, cytokine, dexamethasone, H5N1 avian influenza A virus

Received: October 4, 2007
Accepted December 1, 2008

Glucocorticoids are widely used in the treatment of different inflammatory diseases. The present study was performed to investigate the effect of dexamethasone (DEX) on acute respiratory distress syndrome (ARDS) induced by the H5N1 viral infection in mice.

BALB/c mice, 6–8 weeks old, were divided into three groups with 80 mice in each. The infected group and the DEX-treated infected group were inoculated intranasally with 1x10² 50% mouse infectious dose of A/Chicken/Hebei/108/2002 (H5N1) viruses, with daily intraperitoneal injections of PBS, or 2.5 mg·kg^–1 DEX at days 3–14 post inoculation, respectively. The control group received noninfectious allantoic fluid and a daily intraperitoneal injection of PBS.

In H5N1-infected mice, DEX treatment did not improve the mortality (17 out of 20 versus 16 out of 20 deaths in the DEX-treated infected group versus the infected group), and did not alleviate clinical signs, including weight loss, decreased food intake and inactivity. There was no significant amelioration of the hypoxaemia and ARDS-associated pathological changes in DEX-treated infected mice, as assessed by blood gas analysis and histological score. Furthermore, DEX therapy did not inhibit inflammatory cellular infiltration and cytokine release (interleukin-6 and tumour necrosis factor-) in bronchoalveolar lavage fluid induced by the H5N1 infection.

In conclusion, dexamethasone treatment (2.5 mg·kg^–1) from days 3–14 post inoculation has no beneficial effect on acute respiratory distress syndrome caused by the H5N1 infection in mice.